Uploaded September 2026 | Updated November 2026, 1 day ago
a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines.
Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack.
They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases.
Timestamps:
00:00 - Intro
00:59 - How Moderna Went From COVID to Cancer
02:48 - The Phase 3 News: mRNA Cancer Vaccine + Keytruda in Melanoma
05:46 - What Is Keytruda & Why Isn't It Enough Alone?
09:23 - Preventing the Return of Cancer: What "Vaccine" Really Means Here
11:16 - Why 20 Years and 1,000 Trials Failed Before mRNA Worked
15:09 - Inside the Algorithm: How Moderna Picks the 34 Neoantigens
18:48 - The Operational Lift of Making a Vaccine for Every Patient
20:16 - Vein to Vein: How Fast Can You Deliver a Personalized Vaccine?
24:33 - Manufacturing at Scale & the COGS Question
27:08 - How Do You Regulate a Medicine That's Different Every Time?
29:37 - Beyond Melanoma: Which Cancers Are Next?
35:58 - The Full Arc: From COVID to Cancer to Autoimmune Disease
Resources:
Follow Stéphane Bancel on LinkedIn: linkedin.com/in/st%C3%A9phane-bancel-8185251
Follow Jorge Conde on X: https://x.com/JorgeCondeBio
Stay Updated:
If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Find a16z on X: twitter.com/a16z
Find a16z on LinkedIn: linkedin.com/company/a16z
Listen to the a16z Show on Spotify: open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX
Listen to the a16z Show on Apple Podcasts: podcasts.apple.com/us/podcast/a16z-podcast/id842818711
Follow our host: https://x.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines.
Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack.
They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases.
Timestamps:
00:00 - Intro
00:59 - How Moderna Went From COVID to Cancer
02:48 - The Phase 3 News: mRNA Cancer Vaccine + Keytruda in Melanoma
05:46 - What Is Keytruda & Why Isn't It Enough Alone?
09:23 - Preventing the Return of Cancer: What "Vaccine" Really Means Here
11:16 - Why 20 Years and 1,000 Trials Failed Before mRNA Worked
15:09 - Inside the Algorithm: How Moderna Picks the 34 Neoantigens
18:48 - The Operational Lift of Making a Vaccine for Every Patient
20:16 - Vein to Vein: How Fast Can You Deliver a Personalized Vaccine?
24:33 - Manufacturing at Scale & the COGS Question
27:08 - How Do You Regulate a Medicine That's Different Every Time?
29:37 - Beyond Melanoma: Which Cancers Are Next?
35:58 - The Full Arc: From COVID to Cancer to Autoimmune Disease
Resources:
Follow Stéphane Bancel on LinkedIn: linkedin.com/in/st%C3%A9phane-bancel-8185251
Follow Jorge Conde on X: https://x.com/JorgeCondeBio
Stay Updated:
If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Find a16z on X: twitter.com/a16z
Find a16z on LinkedIn: linkedin.com/company/a16z
Listen to the a16z Show on Spotify: open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX
Listen to the a16z Show on Apple Podcasts: podcasts.apple.com/us/podcast/a16z-podcast/id842818711
Follow our host: https://x.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.



Find a16z on LinkedIn: [https://www.linkedin.com/company/a16z](https://www.linkedin.com/company/a16z)
Listen to the a16z Podcast on Spotify: [https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX](https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX)
Listen to the a16z Podcast on Apple Podcasts: [https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711](https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711)
Follow our host: [https://x.com/eriktorenberg](https://x.com/eriktorenberg)
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see [a16z.com/disclosures](http://a16z.com/disclosures). Robinhood CEO: Making Everyone An Owner](https://i.ytimg.com/vi/ywhugJuzcyE/mqdefault.jpg)


